Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Invested Capital (2016 - 2025)

International Stem Cell (ISCO) has disclosed Invested Capital for 16 consecutive years, with -$3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 6.56% to -$3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.8 million, a 6.56% increase, with the full-year FY2024 number at -$3.9 million, up 6.14% from a year prior.
  • Invested Capital was -$3.8 million for Q3 2025 at International Stem Cell, up from -$3.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of -$3.8 million in Q3 2025 to a low of -$4.7 million in Q3 2022.
  • A 5-year average of -$4.2 million and a median of -$4.3 million in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: tumbled 57.54% in 2021, then rose 17.05% in 2023.
  • International Stem Cell's Invested Capital stood at -$4.6 million in 2021, then grew by 1.48% to -$4.5 million in 2022, then grew by 7.37% to -$4.2 million in 2023, then rose by 6.14% to -$3.9 million in 2024, then increased by 3.92% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Invested Capital are -$3.8 million (Q3 2025), -$3.9 million (Q2 2025), and -$4.1 million (Q1 2025).